NOD2 Antikörper (AA 251-350) (FITC)

Produktnummer ABIN886406

Der Kaninchen-Polyklonal Anti-NOD2-Antikörper wurde für WB und FACS validiert. Er ist geeignet zum Nachweis von NOD2 in Proben aus Human. }

Kurzübersicht für NOD2 Antikörper (AA 251-350) (FITC) (ABIN886406)

Target: NOD2 (Nucleotide-Binding Oligomerization Domain Containing 2 (NOD2))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser NOD2 Antikörper ist konjugiert mit FITC

Applikation: Western Blotting (WB), Flow Cytometry (FACS)

Produktdetails anti-NOD2 Antikörper (FITC)

Bindungsspezifität: AA 251-350

Kreuzreaktivität: Human

Homologie: Mouse,Rat,Dog,Cow,Pig,Horse,Rabbit

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human CARD15

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: FCM 1:20-100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu NOD2

Target: NOD2 (Nucleotide-Binding Oligomerization Domain Containing 2 (NOD2))

Andere Bezeichnung: NOD2

Hintergrund:

Synonyms: ACUG, Arthrocutaneouveal granulomatosis, BLAU, CARD15, Caspase recruitment domain protein 15, Caspase recruitment domain-containing protein 15, IBD1, Inflammatory bowel disease protein 1, LRR containing protein, LRR-containing protein, Nod2, NOD2 protein, NOD2_HUMAN, NOD2B, nucleotide binding oligomerization domain 2, nucleotide-binding oligomerization domain 2, Nucleotide-binding oligomerization domain-containing protein 2, PSORAS1.

Background: Defects in NOD2 are the cause of sarcoidosis early-onset (EOS) . EOS is a form of sarcoidosis manifesting in children younger than 4 years of age. Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved. Early-onset sarcoidosis is quite rare and has a distinct triad of skin, joint and eye disorders, without apparent pulmonary involvement. Compared with an asymptomatic and sometimes naturally disappearing course of the disease in older children, early-onset sarcoidosis is progressive and in many cases causes severe complications, such as blindness, joint destruction and visceral involvement.

Gen-ID: 64127

UniProt: Q9HC29

Pathways: Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Toll-Like Receptors Cascades, Inflammasome